24/7 Market News Snapshot 09 June, 2025 – Lipocine Inc. (NASDAQ:LPCN)

June 9, 2025

DENVER, Colo., 09 June, 2025 (www.247marketnews.com) – (NASDAQ:LPCN) are discussed in this article.
Lipocine Inc. is experiencing positive momentum in the market, with shares opening at $3.03 and currently trading at $3.291, reflecting an increase of 3.82% from the previous session’s close of $3.170. The trading volume has reached 527.90K, indicating a solid interest from investors. The upward price trajectory suggests a bullish sentiment, with a potential breakout above the $3.30 resistance level, while support appears strong around $3.20 should a retracement occur. This trading performance captures the favorable outlook investors have regarding Lipocine’s future.

In a significant development, the company has announced that its licensing partner has submitted a New Drug Submission (NDS) for TLANDO®, the first oral testosterone replacement therapy (TRT) that does not require dose titration, in Canada. This milestone is pivotal in expanding TLANDO’s reach, particularly in a market where testosterone prescriptions exceed 700,000 annually. Mahesh Patel, CEO of Lipocine, expressed his enthusiasm about the NDS filing, highlighting Canada’s attractiveness as a market and the potential for TLANDO to revolutionize the TRT landscape if approved.

With around 50% of the TRT patient population covered by private insurance and limited promotional activity in the current competitive environment, TLANDO is uniquely positioned to fulfill the demand for a more convenient oral alternative. The proprietary Lip’ral technology that supports TLANDO underscores Lipocine’s commitment to developing differentiated and patient-friendly therapeutic options.

Furthermore, in January 2024, Lipocine strengthened its strategic position via an exclusive licensing agreement with Verity Pharma, granting commercial rights to TLANDO in both the United States and Canada. This collaboration is part of Lipocine’s strategy to enhance the accessibility of innovative therapies, positioning the company for future growth and continued development of its therapeutic portfolio.

Related news for (LPCN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.